Allergy Shots: How Long? Every Duration Question Answered

The conventional allergy shot build-up phase takes 8 to 28 weeks of weekly or twice-weekly visits. Most US allergists using a weekly conventional schedule reach the maintenance dose in approximately 6 months — about 25 to 30 injections. The accelerated cluster protocol reaches maintenance in 4 to 8 weeks by administering 2 to 3 escalating doses per session, reducing the total number of clinic visits by roughly 50 percent, per Calabria in Annals of Allergy Asthma Immunology 2023. The rush protocol compresses build-up to 1 to 3 days by giving injections every 15 to 60 minutes in a monitored clinical setting, but it requires premedication and carries higher systemic reaction risk compared to conventional or cluster approaches.

Most patients begin to notice symptom improvement within 3 to 6 months of starting allergy shots — often coinciding with approaching or reaching the maintenance dose. The AAAAI and ACAAI practice parameters by Cox et al. in JACI 2011 state that clinical improvement is usually observed within 1 year after a patient reaches the maintenance dose. Some patients notice early changes within the first few months of the build-up phase, while others require 12 or more months. If no improvement is evident after 1 full year at the maintenance dose, your allergist should reassess allergen selection, dosing adequacy, and whether SCIT remains the appropriate treatment. Treatment duration of 3-plus years strongly predicts clinical remission, per Lee et al. in Allergy, Asthma and Immunology Research 2018.

Post-treatment benefit from allergy shots typically lasts 3 to 12 years after a completed course. Durham et al. established in NEJM 1999 that 3 to 4 years of grass SCIT produced benefit lasting at least 3 years post-discontinuation — with symptom and medication scores remaining as low as during continued maintenance. Eng et al. in Allergy 2006 documented sustained benefit at 12 years post-treatment in a childhood grass SCIT cohort. A 5-year course appears to provide more durable benefit than a 3-year course based on comparative data. Note that 10 to 25 percent of patients experience some symptom recurrence within 3 years of stopping, particularly those who did not complete the full recommended duration.

Yes, venom immunotherapy for Hymenoptera sting allergy follows a different duration model than inhalant allergen SCIT. The standard recommendation is 3 to 5 years of venom IT, after which most patients can safely discontinue with a residual systemic-reaction risk of only 5 to 15 percent over the following decade. However, certain high-risk patients require indefinite venom immunotherapy: those with severe initial systemic reactions, systemic mastocytosis, elevated baseline serum tryptase, honeybee allergy, or patients who experience systemic reactions during venom IT itself. Golden et al. in JACI 2011 and the EAACI Hymenoptera venom allergy guideline by Sturm et al. in Allergy 2018 both support indefinite maintenance in these higher-risk subgroups.

If you stop allergy shots after completing the recommended minimum 3-year course, benefits typically persist for several more years. Durham et al.'s landmark study in NEJM 1999 — the foundational evidence for post-treatment durability — used a 3-to-4-year grass pollen protocol and demonstrated that symptom and medication scores remained significantly lower than placebo for at least 3 years after stopping. The key condition is completing 3 full years: patients who stop earlier have significantly higher relapse rates, per Nouri-Aria et al. in JACI 2004. Individual post-treatment benefit duration varies by allergen type, course completeness, and degree of immune reprogramming achieved.

The AAAAI and ACAAI recommend a minimum of 3 years of maintenance immunotherapy before considering discontinuation. This recommendation derives from evidence that shorter courses — fewer than 3 years — produce significantly less durable post-treatment benefit and higher relapse rates. The EAACI guidelines by Roberts et al. in Allergy 2018 explicitly state that at least 3 years of allergen immunotherapy is required to achieve long-term efficacy persisting after discontinuation. In practice, many allergists extend treatment to 4 to 5 years for patients who are polysensitized, have asthma comorbidity, or show persistent symptoms at the 3-year mark. A 3-year minimum is the floor, not an absolute endpoint.

The gap you can safely take between allergy shots without requiring dose adjustment or a restart depends on which phase you are in and how long the gap is. During maintenance, most allergists permit gaps of up to 5 weeks without dose reduction. A gap of 5 to 7 weeks typically requires reducing the dose by 25 percent; 7 to 11 weeks requires a 45 percent reduction; 8 to 15 weeks typically requires reducing by approximately 55 percent. A gap of 3 to 4 months or longer during maintenance usually requires restarting from the beginning. During build-up, shorter gaps matter more — even a 2-to-3-week delay may require repeating the last dose. These schedules come from the AAAAI Practice Parameter supplement and Larenas-Linnemann et al.'s consolidated guidance in Annals of Allergy 2020.